Activity impairment measures
|
TCZ-SC group
|
csDMARDs-alone group
|
---|
n
|
Standardized regression coefficient
|
95% CI
|
P value
|
n
|
Standardized regression coefficient
|
95% CI
|
P value
|
---|
Presenteeism (%)
|
143
|
−0.4861
|
−0.6470, −0.3252
|
< 0.0001
|
148
|
−0.4328
|
−0.5887, −0.2769
|
< 0.0001
|
Overall work impairment (%)
|
143
|
−0.4819
|
−0.6437, −0.3202
|
< 0.0001
|
148
|
−0.3913
|
−0.5491, −0.2336
|
< 0.0001
|
Activity impairment (%)
|
143
|
−0.6345
|
−0.7747, −0.4943
|
< 0.0001
|
148
|
−0.6486
|
−0.7876, −0.5096
|
< 0.0001
|
HAQ-DI
|
143
|
−0.4828
|
−0.6415, −0.3241
|
< 0.0001
|
148
|
−0.1584
|
−0.3360, 0.0201
|
0.0815
|
EQ-5D
|
143
|
0.3635
|
0.1960, 0.5311
|
< 0.0001
|
148
|
0.3181
|
0.1446, 0.4916
|
0.0004
|
DAS28-ESR
|
143
|
−0.3305
|
−0.4950, −0.1661
|
0.0001
|
148
|
−0.1802
|
−0.3533, −0.0072
|
0.0414
|
CDAI
|
143
|
−0.1950
|
−0.3674, −0.0226
|
0.0270
|
148
|
−0.1127
|
−0.2819, 0.0564
|
0.1897
|
SDAI
|
143
|
−0.2289
|
−0.4003, −0.0576
|
0.0092
|
148
|
−0.1113
|
−0.2810, 0.0585
|
0.1971
|
WFun
|
143
|
−0.3549
|
−0.5266, −0.1832
|
< 0.0001
|
148
|
−0.1680
|
−0.3353, −0.0007
|
0.0491
|
K6
|
143
|
−0.1895
|
−0.3661, −0.0130
|
0.0355
|
148
|
−0.1497
|
−0.3216, 0.0222
|
0.0873
|
- CDAI clinical disease activity index, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-ESR disease activity score in 28 joints using the erythrocyte sedimentation rate, EQ-5D EuroQol 5 dimension, HAQ-DI health assessment questionnaire disability index, K6 6-item Kessler psychological distress scale, SDAI simplified disease activity index, TCZ-SC tocilizumab by subcutaneous injection, WFun work functioning impairment scale